Literature DB >> 8532072

Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.

A Daul1, M Elter-Schulz, U Poller, F Jockenhövel, K Pönicke, F Boomsma, A J Man in't Veld, R F Schäfes, O E Brodde.   

Abstract

Epinine (N-methyl-dopamine, the active metabolite of ibopamine), is a full agonist at dopamine (DA)-receptors and alpha- and beta-adrenoceptors. To study whether in vivo DA-receptors mediated effects can be separated from alpha- and beta-adrenoceptor effects we compared in 10 male volunteers the effects of i.v. epinine (0.5; 1; 2; 4 micrograms/kg/min for 15 min each) on DA-receptor (changes in serum prolactin)- and alpha- and beta-adrenoceptor (changes in systolic [Psyst] and diastolic blood pressure [Pdiast] and heart rate)-mediated effects with those of dopamine before and after propranolol (5 mg i.v. 45 min pre-infusion), bisoprolol (15 mg p.o. 2 h pre-infusion) and domperidone (10 mg p.o. 1 h pre-infusion). At the 0.5 and 1 microgram doses of dopamine and epinine did not effect Psyst, Pdiast and heart rate but significantly decreased prolactin levels. At the higher dose both dopamine and epinine significantly increased Psyst and heart rate, while only epinine significantly increased Pdiast. In addition, both dopamine and epinine significantly increased diuresis and natriuresis; in contrast, only dopamine, but not epinine dose-dependently increased plasma noradrenaline levels. Domperidone did not affect dopamine- and epinine-evoked blood pressure- and heart rate-changes, but antagonized their prolactin-effects (at least at the lower doses). Bisoprolol and propranolol significantly reduced dopamine-induced Psyst- and heart rate-increases to about the same extent. Propranolol enhanced epinine-induced Psyst- and Pdiast-increases while bisoprolol reduced epinine-evoked Psyst-increase but not Pdiast-increase. Epinine-induced heart rate-increase was abolished by bisoprolol and was converted into heart rate-decrease by propranolol. We concluded that in 0.5 and 1 microgram doses (plasma levels of 20-80 nmol/l)epinine acts only at DA-receptors. Thus, ibopamine in therapeutically recommended doses (3 x 100 mg/day with peak plasma epinine-levels of 50-80 nmol/l) very likely activates only DA-receptors. In higher doses, however, epinine-like dopamine-activates alpha- and beta-adrenoceptors whereby epinine has a stronger alpha-adrenoceptor agonistic activity than dopamine. Moreover, part of the dopamine-effects are indirect via release of endogenous noradrenaline whereas epinine-effects do not appear to include an indirect component.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532072     DOI: 10.1007/bf00172781

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  44 in total

1.  Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.

Authors:  J D Port; E M Gilbert; P Larrabee; P Mealey; K Volkman; R Ginsburg; R E Hershberger; J Murray; M R Bristow
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

2.  Dopamine and the kidney: ten years on.

Authors:  M R Lee
Journal:  Clin Sci (Lond)       Date:  1993-04       Impact factor: 6.124

3.  Studies on the positive inotropic effect of dopamine in the guinea-pig heart.

Authors:  A Mugelli; F Ledda; L Mantelli; M Torrini; T Maccioni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-12       Impact factor: 3.000

4.  Dopamine during alpha- or beta-adrenergic blockade in man. Hormonal, metabolic, and cardiovascular effects.

Authors:  M Lorenzi; J H Karam; E Tsalikian; N V Bohannon; J E Gerich; P H Forsham
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

5.  Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.

Authors:  A J Nichols; R R Ruffolo
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

6.  The metabolic effects of dopamine in man.

Authors:  A Pernet; V A Hammond; G Blesa-Malpica; J Burrin; H Orskov; K G Alberti; D G Johnston
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy.

Authors:  F L Anderson; J D Port; B B Reid; G Hanson; A C Kralios; R E Hershberger; M R Bristow
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

8.  Effects of ibopamine on exercise-induced increase in norepinephrine in normal men.

Authors:  A R Girbes; D J Van Veldhuisen; R G Grevink; A J Smith; W D Reitsma
Journal:  J Cardiovasc Pharmacol       Date:  1992-03       Impact factor: 3.105

9.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

10.  Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.

Authors:  A M Katz
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

View more
  2 in total

1.  Losartan reduces mortality in a genetic model of heart failure.

Authors:  Sophie Günther; Hideo A Baba; Steffen Hauptmann; Hans-Jürgen Holzhausen; Claudia Grossmann; Karla Punkt; Tina Kusche; Larry R Jones; Ulrich Gergs; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-10       Impact factor: 3.000

2.  Dopamine D2 receptor upregulates leptin and IL-6 in adipocytes.

Authors:  Xiaoyan Wang; Van Anthony Villar; Andrew Tiu; Kiran K Upadhyay; Santiago Cuevas
Journal:  J Lipid Res       Date:  2018-02-22       Impact factor: 5.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.